Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 17/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229080 | 1.00 | MAOA (0.56) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL5238263 | 0.89 | MAOA (0.72) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL5230590 | 0.86 | MAOA (0.42) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL5233903 | 0.84 | MAOA (0.56) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL5232210 | 0.83 | MAOA (0.80) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL5233940 | 0.83 | MAOA (0.57) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL5234584 | 0.82 | MAOA (0.56) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL5742132 | 0.82 | MAOA (0.68) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL5743011 | 0.82 | MAOA (0.68) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL5742127 | 0.82 | MAOA (0.68) | MAOAMAOBCYP3A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385844-B1 | OXAZOLIDINONES CONTAINING A SULFONIMID GROUP AS ANTIBIOTICS | ASTRAZENECA AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20050032861-A1 | Oxazolidines containing a sulfonimid group as antibiotics | ASTRAZENECA AB (SE) | 2005-02-10 | — | — | US | disclosed |
| EP-1385844-A1 | OXAZOLIDINONES CONTAINING A SULFONIMID GROUP AS ANTIBIOTICS | Astrazeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002081470-A1 | OXAZOLIDINONES CONTAINING A SULFONIMID GROUP AS ANTIBIOTICS | ASTRAZENECA AB (SE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032861-A1 | Oxazolidines containing a sulfonimid group as antibiotics | SULT1E1, STS, OXA1L | MAOA 963/4885MAOB 357/4885CYP3A4 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.